OBJECTIVE: Chronic inflammation is suspected to have a role in breast carcinogenesis. Results of studies of non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer have been inconsistent. Timing of exposure and analysis of individual NSAIDs should be considered. METHODS: We conducted a population-based case-control study in western New York State between 1996 and 2001. Cases, 35-79 years, had incident, primary, histologically confirmed breast cancer (n = 1,170). Controls (n = 2,115) were randomly selected from NY Department of Motor Vehicles records (<65 years) or Medicare rolls (>or=65 years). Participants were queried on use of aspirin, ibuprofen, and acetaminophen in the year prior and on aspirin during adulthood. Unconditional logistic regression was used to estimate adjusted odds ratios (OR) and 95% confidence intervals (95% CI). RESULTS: Recent aspirin use was inversely associated with breast cancer risk (adjusted OR 0.80, 95% CI: 0.68-0.94); the strongest reduction in risk was observed among those who took >or=2 pills/day on days that aspirin was taken (OR 0.74, 95% CI: 0.61-0. 90). Adult lifetime use was also associated with breast cancer risk (>10 days/month, adjusted OR 0.68, 95% CI: 0.46-1.00). Use of ibuprofen or acetaminophen was not associated with breast cancer. CONCLUSIONS: This is the first study to investigate the association of adult lifetime aspirin intake with breast cancer risk. Our findings provide evidence that aspirin use throughout a woman's life may confer some benefit.
OBJECTIVE:Chronic inflammation is suspected to have a role in breast carcinogenesis. Results of studies of non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer have been inconsistent. Timing of exposure and analysis of individual NSAIDs should be considered. METHODS: We conducted a population-based case-control study in western New York State between 1996 and 2001. Cases, 35-79 years, had incident, primary, histologically confirmed breast cancer (n = 1,170). Controls (n = 2,115) were randomly selected from NY Department of Motor Vehicles records (<65 years) or Medicare rolls (>or=65 years). Participants were queried on use of aspirin, ibuprofen, and acetaminophen in the year prior and on aspirin during adulthood. Unconditional logistic regression was used to estimate adjusted odds ratios (OR) and 95% confidence intervals (95% CI). RESULTS: Recent aspirin use was inversely associated with breast cancer risk (adjusted OR 0.80, 95% CI: 0.68-0.94); the strongest reduction in risk was observed among those who took >or=2 pills/day on days that aspirin was taken (OR 0.74, 95% CI: 0.61-0. 90). Adult lifetime use was also associated with breast cancer risk (>10 days/month, adjusted OR 0.68, 95% CI: 0.46-1.00). Use of ibuprofen or acetaminophen was not associated with breast cancer. CONCLUSIONS: This is the first study to investigate the association of adult lifetime aspirin intake with breast cancer risk. Our findings provide evidence that aspirin use throughout a woman's life may confer some benefit.
Authors: Randall E Harris; Rowan T Chlebowski; Rebecca D Jackson; David J Frid; Joao L Ascenseo; Garnet Anderson; Aimee Loar; Rebecca J Rodabough; Emily White; Anne McTiernan Journal: Cancer Res Date: 2003-09-15 Impact factor: 12.701
Authors: Mary Beth Terry; Marilie D Gammon; Fang Fang Zhang; Heba Tawfik; Susan L Teitelbaum; Julie A Britton; Kotha Subbaramaiah; Andrew J Dannenberg; Alfred I Neugut Journal: JAMA Date: 2004-05-26 Impact factor: 56.272
Authors: H T Sørensen; S Friis; B Nørgård; L Mellemkjaer; W J Blot; J K McLaughlin; A Ekbom; J A Baron Journal: Br J Cancer Date: 2003-06-02 Impact factor: 7.640
Authors: Theodore M Brasky; Matthew R Bonner; Kirsten B Moysich; Christine B Ambrosone; Jing Nie; Meng Hua Tao; Stephen B Edge; Bhaskar V S Kallakury; Catalin Marian; David S Goerlitz; Maurizio Trevisan; Peter G Shields; Jo L Freudenheim Journal: Cancer Causes Control Date: 2011-04-23 Impact factor: 2.506
Authors: Yanli Li; Theodore M Brasky; Jing Nie; Christine B Ambrosone; Susan E McCann; Peter G Shields; Maurizio Trevisan; Stephen B Edge; Jo L Freudenheim Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-11-08 Impact factor: 4.254
Authors: Theodore M Brasky; Matthew R Bonner; Kirsten B Moysich; Heather M Ochs-Balcom; Catalin Marian; Christine B Ambrosone; Jing Nie; Meng Hua Tao; Stephen B Edge; Maurizio Trevisan; Peter G Shields; Jo L Freudenheim Journal: Breast Cancer Res Treat Date: 2010-07-30 Impact factor: 4.872
Authors: Jaclyn L F Bosco; Julie R Palmer; Deborah A Boggs; Elizabeth E Hatch; Lynn Rosenberg Journal: Cancer Causes Control Date: 2011-08-30 Impact factor: 2.506
Authors: Luisel J Ricks-Santi; Jing Nie; Catalin Marian; Heather M Ochs-Balcom; Maurizio Trevisan; Stephen B Edge; Yasmine Kanaan; Jo L Freudenheim; Peter G Shields Journal: Genet Epidemiol Date: 2013-05-14 Impact factor: 2.135
Authors: Xuehong Zhang; Stephanie A Smith-Warner; Laura C Collins; Bernard Rosner; Walter C Willett; Susan E Hankinson Journal: J Clin Oncol Date: 2012-08-27 Impact factor: 44.544